Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?
Table 2
Updated phase III randomised trials on hypofractionation for prostate cancer. All results are statistically significant, except those marked with n.s.
Median FU (yrs)
Dose (Gy) per fraction
Benefit bDFS (%)
Toxicity Gr2 GI (%)
Toxicity Gr2 GU (%)
Dutch trial
Aluwini et al. 2015
820
5
39 × 2 versus 19 × 3.4
77 versus 80
Equal; 13
22 versus 23
RTOG 0415
Lee et al. 2016
1092
5.8
41 × 1.8 versus 28 × 2.5
85.3 versus 86.3
11.4 versus 18.3
20.5 versus 26.2
CHHiP
Dearnaley et al. 2016
3163
5.1
37 × 2 versus 20 × 3 versus 19 × 3
88.3 versus 90.6 versus 85.9
Equal; 2
11 versus 13
bDFS: biochemical disease-free survival; CHHiP: conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer; n.s.: not significant; Gr2: grade 2 or more toxicity.